Harmony Biosciences Holdings (HRMY) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.

Total Cash From Operating Activities Chart for Harmony Biosciences Holdings

Harmony Biosciences Holdings (HRMY) operating cash flow for FY2025 was USD 348.2M, a 58.4% change from FY2024. Harmony Biosciences Holdings's operating cash flow moved from USD -38.8M in 2018 to USD 348.2M in 2025 over 7 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.10B
Implied Share Price
$36.13
Enterprise Value
$1.91B
Revenue (TTM)
$959.90M
EBITDA
$255.99M
Profit Margin
18.88%
Trailing P/E
11.65
Forward P/E
10.32
Price/Book (MRQ)
2.42
Price/Sales (TTM)
2.19
EV/EBITDA
6.80
EV/Revenue
1.98
Dividend Yield
—
Book Value
$17.19
Free Cash Flow (FY2025)
$347.89M
Free Cash Flow Yield
16.53%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.